

1 Evaluation of the systemic and mucosal immune 2 response induced by COVID-19 and the BNT162b2 3 mRNA vaccine for SARS-CoV-2

4 **Olaf Nickel**^{‡,1}, **Alexandra Rockstroh**^{‡,2,9}, **Johannes Wolf**^{‡,3}, **Susann Landgraf**⁴,
5 **Sven Kalbitz**⁵, **Nils Kellner**^{3,5}, **Michael Borte**^{3,4}, **Jasmin Fertey**^{2,9}, **Christoph**
6 **Lübbert**^{5,6,7}, **Sebastian Ulbert**^{‡,9} and **Stephan Borte**^{‡,* 1,3,8}

7
8 ¹ Department of Laboratory Medicine, Hospital St. Georg, Leipzig, Germany;

9 ² Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany;

10 ³ ImmunoDeficiencyCenter Leipzig, Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiency Diseases, Hospital St.
11 Georg, Leipzig, Germany;

12 ⁴ Hospital Vaccination Center, Hospital St. Georg, Leipzig, Germany;

13 ⁵ Department of Infectious Diseases/Tropical Medicine, Nephrology and Rheumatology, Hospital St. Georg, Leipzig, Germany;

14 ⁶ Interdisciplinary Center for Infectious Diseases, Leipzig University Hospital, Leipzig, Germany;

15 ⁷ Division of Infectious Diseases and Tropical Medicine, Department of Medicine II, Leipzig University Hospital, Leipzig, Germany;

16 ⁸ Division of Clinical Immunology and Transfusion Medicine, Department of Laboratory Medicine, Karolinska Institutet, Karolinska
17 University Hospital Huddinge, Stockholm, Sweden.

18 ⁷ Division of Infectious Diseases and Tropical Medicine, Department of Medicine II, Leipzig University Hospital, Leipzig, Germany;

19 ⁸ Division of Clinical Immunology and Transfusion Medicine, Department of Laboratory Medicine, Karolinska Institutet, Karolinska
20 University Hospital Huddinge, Stockholm, Sweden.

21 ⁹ Fraunhofer Cluster of Excellence Immune-Mediated Diseases CIMD, Leipzig, Germany

22 [‡] authors contributed equally

23 ^{*}corresponding author

24
25 **Keywords:** COVID-19, SARS-CoV-2, vaccination, BNT162b2, neutralizing antibodies

26 27 **Manuscript main points:**

28 Immune responses towards BNT162b2 mRNA vaccination were studied prospectively and
29 revealed immunoprotective systemic effects for SARS-CoV-2 wildtype and the VOCs
30 B.1.617.2 and B.1.351. No relevant effect on mucosal immunity could be detected. Vaccine
31 responses indicated decreased efficacy towards B.1.617.2 and B.1.351 variant-of-concern in
32 neutralization assays.

33 34 35 36 **Corresponding author:**

37 Stephan Borte, MD, PhD

38 Head of the Department of Laboratory Medicine

39 Hospital St. Georg Leipzig

40 Delitzscher Strasse 141

41 D-04129 Leipzig

42 Germany

43 eMail: Stephan.Borte@sanktgeorg.de

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

44 Phone: +49 (341) 909 3019

45 **ABSTRACT**

46 **Background**

47 Currently used vaccines to protect from COVID-19 mostly focus on the receptor-binding
48 domain (RBD) of the viral spike protein, and induced neutralizing antibodies have shown to be
49 protective. However, functional relevance of vaccine-generated antibodies are poorly
50 understood on variants-of-concern (VOCs) and mucosal immunity.

51 **Methods**

52 We compared specific antibody production against the S1 subunit and the RBD of the spike
53 protein, the whole virion of SARS-CoV-2, and monitored neutralizing antibodies in sera and
54 saliva of 104 BNT162b2 vaccinees and 57 individuals with natural SARS-CoV-2 infection.
55 Furthermore, we included a small cohort of 11 individuals which received a heterologous
56 ChAdOx1-S/BNT162b2 prime-boost vaccination.

57 **Results**

58 Vaccinated individuals showed higher S1-IgG antibodies in comparison to COVID-19 patients,
59 followed by a significant decrease 3 months later. Neutralizing antibodies (nAbs) were poorly
60 correlated with initial S1-IgG levels, indicating that these might largely be non-neutralizing. In
61 contrast, RBD IgGAM was strongly correlated to nAbs, suggesting that RBD-IgGAM is a
62 surrogate marker to estimate nAb concentrations after vaccination. The protective effect of
63 vaccine- and infection-induced nAbs was found reduced towards B.1.617.2 and B.1.351 VOCs.
64 NAb titers are significantly higher after third vaccination compared to second vaccination. In
65 contrast to COVID-19 patients, no relevant levels of RBD specific antibodies were detected in
66 saliva samples from vaccinees.

67

68

69 **Conclusions**

70 Our data demonstrate that BNT162b2 vaccinated individuals generate relevant neutralizing
71 antibodies, which begin to decrease within three months after immunization and show lower
72 neutralizing potential to VOCs as compared to the original Wuhan virus strain. A third booster
73 vaccination provides a stronger nAb antibody response than the second vaccination. The
74 systemic vaccine does not seem to elicit readily detectable mucosal immunity.

75

76 **INTRODUCTION**

77 Starting from the pandemic spread of the coronavirus disease in December 2019 (COVID-19),
78 global research efforts were made to identify effective vaccine candidates. Vaccines based on
79 vectors, inactivated viruses and mRNA were licensed, whereas the latter comprises a novel
80 immunization technology. However, the kinetics of SARS-CoV-2 antibody production and the
81 persistence of humoral immunity following such a vaccination over time is of great interest for
82 national health services and the management of the pandemic. Recent studies suggested that
83 SARS-CoV-2 specific antibody production following vaccination with the BNT162b2
84 (BioNTech/Pfizer) mRNA vaccine is comparable to seroconversion following recovery from
85 COVID-19.[1] During SARS-CoV-2 infection, the median time to detect circulating antibodies
86 has been reported at 11 days after the onset of symptoms and this period will be affected by
87 initial disease severity.[2] In patients with milder symptoms, some antibodies wane rapidly,
88 especially IgG against the nucleocapsid protein, whereas our group and others have shown that
89 antibodies to the spike protein and neutralizing antibodies remain detectable much longer.[3-5]
90 We performed a prospective study after the second BNT162b2 vaccination and assessed the
91 longevity of vaccine-induced antibodies for three and eight months in follow-up visits and
92 compared it with the humoral immune response after a third booster vaccination. Furthermore,

93 we analyzed effectiveness and kinetic of BNT162b2-induced nAbs against the variants of
94 concern B.1.351 (Beta) and B.1.617.2 (Delta) and. [6, 7] and the impact of the homologous
95 BNT162b2 booster vaccination. Moreover, we also dissected the SARS-CoV-2 specific
96 antibody production in individuals that were vaccinated with a heterologous ChAdOx1-S vector
97 vaccine (AstraZeneca) and BNT162b2 mRNA vaccine (BioNTech/Pfizer) prime-boost regime.
98 In addition to systemic immunity, mucosal immune responses are considered to be critically
99 important in reducing SARS-CoV-2 spread. By mediation of the mucosa-associated lymphoid
100 tissue (MALT), a strong suppression of SARS-CoV-2 transmission can be achieved due to the
101 blockage of viral entry in mucosal cells of the oral cavity and pharynx. In saliva of recovered
102 COVID-19 patients, IgA antibodies are detectable in high concentrations.[8] Based on the route
103 of application, it remains unclear if homologous mRNA or heterologous mRNA-vector
104 vaccination might elicit a partial mucosal immune response or does not provide any benefit in
105 generating a sterile mucosal immunity.

107 PATIENTS AND METHODS

108 Study design and human samples

109 The study included two cohorts of vaccinated individuals that were followed prospectively and
110 previously bio-banked samples from COVID-19 patients (Fig 1, Table 1). Study participants
111 receiving homologous vaccination with the BNT162b2 mRNA vaccine (BNT/BNT, n=104,
112 EMA fact sheet[9]) were recruited among healthcare employees at the Hospital St. Georg in
113 Leipzig, Germany. Serum and saliva samples were collected on the day of first dose of
114 vaccination (V1), on the day of the second dose vaccination (V2, median 21 days [IQR 21-22]
115 after V1), and 14 to 28 days after the second dose vaccination (P1, median 42 days [IQR 42-
116 43] after V1). We collected additional serum samples and dried blood spot samples (DBS) at
117 time points P2 (25 individuals, 76 to 102 days after V2, median 102 days [IQR 99-109] after
118 V1), P3 (41 individuals, [IQR 251-260] days after V2) and after booster vaccination (20
119 individuals, [IQR 14-16] days after P3).

120 **Fig 1.** Time points of blood sampling within the different cohorts in median days (min - max)
121 Vaccinees: V1 prior first vaccination, V2 21 days (21-27), P1 42 (35-49), P2 102 days (98-127) and P3 276 days
122 (252-286) after first vaccination. Boost samples were taken 309 (271-335) after first vaccination.

123 Homologous BNT162b2 vaccinees received their second vaccination 3 weeks after the first dose, whereas
124 heterologous vaccinees received their second dose (BNT16b2) 10 weeks after the first vaccination with ChAdOx1-
125 S

126 COVID-19 Patients: 35 days post symptom onset (PSO) (7-43)

127

128 Another 11 study participants (63.6 % females, median age 31 [IQR 26-37]) received a
129 heterologous ChAdOx1-S vector based prime (EMA fact sheet [10]) and BNT162b2 boost
130 vaccination (AZ/BNT). In accordance to the homologous BNT/BNT group, serum samples
131 were collected on the day of the first dose of ChAdOx1-S vaccination (V1), 21 days after V1
132 (V2, median 21 days [IQR 20-22] after V1), and 12 to 15 days after second dose vaccination
133 (P1, median 91 days [IQR 90-92] after V1).

134 Inclusion into the study was independent of a previous SARS-CoV-2 infection. The ethics
135 committee of the Saxonian medical chamber approved the study (registry number EK-allg-
136 37/10–1) and informed consent was obtained from all volunteers.

137 As reference, 57 PCR-confirmed COVID-19 patients were included, which were treated
138 between March 3 and November 11, 2020, at the Department of Infectious Diseases/Tropical
139 Medicine, Nephrology and Rheumatology of the Hospital St. Georg. Serum samples were
140 collected between 7 and 43 days (Median 35 days, IQR 20-44) after symptoms onset. COVID-
141 19 patients were stratified into two groups according to the WHO clinical progression scale
142 (*World Health Organization 2020 ordinal scale for clinical improvement*): (1) “mild”, scale
143 values 2 or 3 and (2) “moderate/severe” with scale values 4 or 5. For 29 of 34 COVID-19
144 patients with moderate/severe progression, saliva was collected (Table 1).

145 Table 1: Demographic characteristics of vaccinees and COVID-19 cases

	Homologous vaccinees (BNT)	Heterologous vaccinees (AZ/ BNT)	COVID-19 patients
N	104	11	57
Females (%)	68.3*	63.6*	43.9
Median age (min-max)	41 (20-66)	31* (26-37)	51 (32-79)
Median days after first dose (min-max)			
V2	21 (21-27)	21 (20-22)	
P1	42 (35-49)	91 (90-92)	-
P2 ¹	102 (98-127)	-	
P3	276 (252-286)	-	
Boost	309 (271-335)	-	
Median days after the onset of symptoms (min-max)	-	-	35 (7-43)
Vaccination reaction (%):			

None	11.5	0	-
Local ²	14.4	0	-
Systemic ³	74.0	100	-
severity of disease ⁴ (%)			
mild (scale 2-3)	-	-	57.9
moderate/severe (scale 4-5)	-	-	42.1

146 ¹ blood sampling was done for 25 of 104 volunteers ² pain at the vaccination site. ³ includes fever, chills,
147 headache, fatigue, nausea, diarrhea, body aches, and nerve pain. ⁴ Clinical severity of COVID-19
148 patients was classified according to the WHO clinical progression: (2) ambulatory without limitation of
149 activity, (3) hospitalized without oxygen, (4) hospitalized on oxygen therapy by mask or nasal prongs,
150 (5) hospitalized receiving non-invasive ventilation or high-flow oxygen therapy. Mann-Whitney-U test
151 was used to analyze differences in age and Fisher's exact test was applied to evaluate difference in
152 gender (* p<0.05, **p<0.01). d = days, IQR = inter quartile range, n.s.= not significant. AZ =
153 AstraZeneca (ChAdOx1-S), BNT = BioNTech/Pfizer (BNT162b2), V2 = three weeks after first
154 vaccination, P1 = two weeks after second vaccination, P2 = three month after second vaccination

155

156 **Commercial assays for the detection of antibodies against S1 and Nucleocapsid**

157 All serum samples were tested for IgG against SARS-CoV-2 S1 (Anti-SARS-CoV-2-
158 QuantiVac-ELISA, S1 Quant IgG; cut-off ≥ 25.6 BAU/ml) and for IgA against SARS-CoV-2
159 S1 (S1 IgA, Euroimmun, Lübeck, Germany; cut-off ratio ≥ 0.8). Samples above detection limit
160 for S1 Quant IgG were pre-diluted 1:10 and 1:50 in sample buffer. In addition, baseline sera
161 were screened for IgG antibodies against SARS-CoV-2 nucleocapsid (Virotech, Rüsselsheim,
162 Germany; cut-off ≥ 11 VE/ml).

163

164 **In-house developed enzyme-linked immunosorbent assays**

165 Detection of SARS-CoV-2 inactivated whole virion (IWV) IgG-antibodies and SARS-CoV-2
166 RBD polyvalent IgGAM-antibodies was performed according to Rockstroh *et al.* 2021.[3]
167 Briefly, Nunc PolySorp plates were coated with 1.5 μ l per well of inactivated SARS-CoV-2 wt
168 viral particles and 250 ng/well of RBD protein in 100 μ l per well of carbonate coating buffer
169 (15 mM Na₂CO₃, 7 mM NaHCO₃ pH 9.6) overnight at 4°C. RBD protein (AA residues 329-

170 538 of spike protein, strain Wuhan-Hu-1) was expressed in *Drosophila* S2 cells and purified
171 from cell culture supernatants with tandem immobilized metal affinity and size exclusion
172 chromatography using the ÄKTA pure 25 1 chromatography system (GeHealthcare).
173 SARS-CoV-2 viral particles were purified from infectious cell culture supernatants by
174 ultracentrifugation on a 30 % sucrose cushion in MSE buffer (10 mM MOPS, pH 6.8, 150 mM
175 NaCl, 1 mM EDTA) at 25,000 rpm for 3.5 h and 4°C. The pellet was resuspended in MSE
176 buffer and chemically inactivated with 0.1 % beta-propiolactone at 22°C. Sera (diluted 1:100)
177 were incubated for 1.5 h at room temperature and binding antibodies were detected using a
178 HRP-conjugated secondary goat anti human IgG antibody (Dianova, 1:20,000) or goat anti
179 human IgG+IgM+IgA H&L antibody (Abcam, 1:10,000) for 1 h at room temperature. TMB
180 substrate (Biozol) was added after a final wash step and incubated for 25 minutes before the
181 reaction was stopped with 1 M H₂SO₄. Absorbance was detected at 450 nm with 520 nm as
182 reference in a microplate reader (Tecan). The cut-off values were determined for each antigen
183 individually and were validated using 100 pre-pandemic serum samples. All measurements
184 were performed at least in duplicates.

185

186 **SARS-CoV-2 viral stocks**

187 SARS-CoV-2 wildtype virus (wt) (isolate BetaCoV/Germany/BavPat1/2020, obtained from the
188 European Virus Archive Global, EVAg)[11], SARS-CoV-2 B.1.1.7 (isolate MUC1-IMB1-CB,
189 kindly provided by Klaus Überla from the Institute of Clinical and Molecular Virology,
190 University of Erlangen-Nürnberg) and SARS-CoV-2 B.1.351 (SARS-CoV-
191 2/human/Germany/LE-B14HXA2/2021 kindly provided by Corinna Pietsch from the Institute
192 of Virology, University Hospital Leipzig) were propagated in VeroE6 cells. Cells were grown
193 to a confluence of approx. 80 - 90 % and were infected at a MOI of 0.001 in Dulbecco's
194 modified Eagle's medium (DMEM), supplemented with 2 % FCS and 1 % Pen/Strep. They

195 were incubated for 48 h at 37°C with 5 % CO₂ until cytopathic effect (CPE) was visible. Virus
196 containing supernatants were centrifuged at 4000 g for 10 min at 4°C and then stored at -80°C
197 until use. Viral titers were determined using a focus-forming assay. All viral stocks were
198 sequenced to verify their spike protein sequences and expected mutation sites.

199

200 **SARS-CoV-2 neutralization assay**

201 Focus reduction neutralization assays (FRNT) were performed according to Rockstroh *et. al.*
202 2021.[3] Briefly, heat-inactivated human serum samples were serially diluted in DMEM
203 without FCS from 1:2.5 to 1:5120 and incubated with 50-150 focus forming units of SARS-
204 CoV-2 wt, B.1.1.7 or B.1.351 for 1 h at 37°C before addition to confluent Vero E6 monolayers
205 in 96-well plates. After an incubation of 1 h at 37°C, supernatant was removed, cells were
206 washed with PBS, overlaid with 1 % Methyl cellulose in DMEM with 2 % FCS and incubated
207 for 24-26 h at 37°C in 5 % CO₂. Cells were fixed with 4% paraformaldehyde in PBS,
208 permeabilized and blocked with Perm-Wash buffer (0.1% saponin, 0.1% BSA in PBS). SARS-
209 CoV-2 focus forming units were stained using a monoclonal rabbit anti-S1 antibody (CR3022,
210 abcam, 1:1,000) and a secondary goat anti-rabbit IgG HRP-conjugated antibody (Dianova,
211 1:1,000). After the addition of TrueBlue substrate (Seracare), spots were counted with an
212 ELISpot reader (AID Diagnostika). FRNT₉₀ titers were determined as the reciprocal of the last
213 dilution providing a minimum of 90 % neutralization of focus forming units in comparison to
214 the virus control without serum. A positivity cut-off of FRNT₉₀ ≥5 was determined with
215 negative reference sera, data not shown.

216

217

218

219 **Collection and detection of SARS-CoV-2 specific IgA in saliva**

220 Saliva was collected using the Oracol Saliva Collection System (Oracol, Worcester, U.K.)
221 according to the manufacturer's specification. Aliquots were stored at -80°C in Protein Low-
222 Bind microtubes (Eppendorf, Hamburg, Germany) until further use. Samples were centrifuged
223 at 10,000 g for 5 min and the supernatant was collected. 25 µl of saliva was mixed with equal
224 amounts of LEGENDplex assay buffer and S1- or RBD-coated beads in a 5 ml polypropylene
225 FACS tube, sealed and incubated overnight at 7°C in the dark. Subsequently, the bead mixture
226 was washed with 1 ml of LEGENDplex wash buffer at 250 g for 5 min and incubated with 25µl
227 of Streptavidin-conjugated anti-IgA detection antibody for 60 min on an orbital shaker at 800
228 rpm, followed by the addition of 25 µl of Streptavidin-PE conjugate for another 30 min (all
229 from BioLegend, SanDiego, CA, U.S.). After another wash step, beads were resuspended in
230 500 µl of BD sheath fluid and analyzed using a BD FACS Lyric flow cytometer (BD
231 Biosciences, San Jose, CA, U.S.) with PMT voltage settings adapted to discriminate beads
232 specific for Spike S1- and Spike RBD-specific IgA antibodies. Binding of IgA antibodies was
233 evaluated as median fluorescence signals on detected beads.

234

235 **Study design and human samples**

236 For comparison of surrogate neutralizing antibody concentrations to SARS-CoV-2 in dried
237 blood spot samples DBS, we included samples of 63 COVID-19 patients (53.9% female,
238 median age 61 years, IQR 48-72) collected between 60 and 319 days (Median 177 days, IQR
239 146-258) after disease onset.

240

241

242

243 **Validation of a dried blood spot based surrogate assay for SARS-CoV-2 nAbs**

244 Given the superior value and importance of a correlate of serological neutralizing activity in
245 SARS-CoV-2 vaccinated individuals and COVID-19 patients, as well as to monitor seasonal
246 booster vaccinations, we intended to develop and validate a simple diagnostic platform using
247 DBS. This ACE-2 competitive-binding assay uses non-purified serum eluates from DBS and is
248 scalable in a 96-well format for automated analysis on a suitable reader system capable of
249 detecting fluorophore-conjugated microbeads.

250 With this approach, we could verify neutralizing surrogates both in mild and severe COVID-
251 19 courses, as well as in BNT162b2-vaccinated individuals, with the latter two showing
252 comparable levels as previously shown in the assessment of neutralizing antibodies using our
253 focus reduction neutralization assay (FRNT) with serum samples. Therefore, we compared
254 FRNT-suggested nAb titers in matched serum samples with calculated concentrations of
255 neutralizing surrogate antibodies in DBS and found a high degree of correlation (S3).

256

257 **Detection of surrogate neutralizing antibodies to SARS-CoV-2 in saliva and dried blood** 258 **spot samples**

259 Dried blood spot samples (DBS) were generated by applying peripheral venous blood on a GE
260 Healthcare / Whatman 903 filter paper (Little Chalfont, U.K.) allowed to dry at room
261 temperature for at least 4 hours. DBS were stored at 7°C until further use. 2 x 3.2 mm dots were
262 generated using a PerkinElmer Wallac punching device and were sorted into 96-well 0.45 µM
263 PVDF plates (Merck Millipore, Billerica, MA, U.S.) with plate outlets sealed with a foil. 70 µl
264 of LEGENDplex assay buffer was applied and plates were sealed on top, centrifuged at 1000 g
265 for 2 min and stored at 7°C overnight. The outlet foil then was removed and the DBS suspension
266 was drained from the plates by centrifugation at 1000 g for 5 min into a 96-well Protein

267 LowBind plate (Eppendorf, Hamburg, Germany). Saliva samples were collected, stored and
268 prepared as depicted above. 50 µl of DBS suspension or saliva was combined in a 5 ml
269 polypropylene FACS tube together with 25 µl of SARS-CoV-2 neutralizing antibodies and 25
270 µl of SARS-CoV-2 neutralizing assay beads B3 (all from BioLegend, San Diego, CA, U.S.) and
271 kept on an orbital shaker for 120 min at 800 rpm. Subsequently, the bead mixture was incubated
272 with 25 µl of Streptavidin-PE conjugate for another 30 min and finally washed with 1 ml of
273 LEGENDplex wash buffer at 250 g for 5 min. Beads were resuspended in 500 µl of BD sheath
274 fluid and analyzed using a BD FACS Lyric flow cytometer with PMT voltage settings adapted
275 to detect beads specific for the ACE2 neutralization target. Binding of neutralizing antibodies
276 inversely correlates with the median fluorescence signal detected on beads.

277

278 **Statistical analysis**

279 SPSS version 21 (IBM, Armonk, NY, USA) and GraphPad PRISM version 6 (GraphPad
280 Software, San Diego, CA, USA) were used for statistical calculations and generation of figures.
281 Statistical tests were calculated as paired or unpaired one-way ANOVA with Holm-Sidak's
282 multiple comparison test for the analysis of follow-up samples or vaccine and infection induced
283 antibodies, respectively. Fisher's exact test was applied for comparison of categorical variables.

284

285 **RESULTS**

286 **Serological characterization of BNT162b2 vaccinees and COVID-19 patients**

287 Among 104 individuals receiving a homologous BNT162b2 vaccination we analyzed S1, RBD,
288 inactivated whole virion (IWV) and neutralizing antibodies and drew comparisons to 57
289 COVID-19 patients with mild and severe courses serving as reference group (Table 1, Fig 2 A-

290 E).[3] SARS-CoV-2 neutralizing as well as S1, RBD and IWV binding antibodies were
291 detectable in most individuals three weeks after the first vaccination. Two weeks after the
292 second dose, nAb titers and binding antibodies to all tested antigens were significantly
293 increased. At this stage, nAb titers (Median FRNT₉₀ = 320) as well as IWV IgG antibody signals
294 were comparable to those induced by natural mild COVID-19 but did not reach the high levels
295 of patients having severe COVID-19 courses (4- and 1.3- fold decrease for nAb and IWV IgG
296 respectively) (Fig 2 A and E). In contrast, RBD IgGAM and S1 IgA antibody levels
297 corresponded to those induced after severe COVID-19 and were even significantly exceeded
298 by vaccine-induced S1 IgG antibodies (3.5 fold increase). For some individuals, IgG antibodies
299 against the inactivated whole virion of SARS-CoV-2 (IWV) were detected even before the first
300 vaccination.

301 **Fig 2.** BNT162b2 vaccination induced antibodies in comparison to SARS-CoV-2 infection induced antibodies
302 The presented data shows antibody ratios before first (V1), 3 weeks after first (V2), and 2 weeks after second
303 vaccination (P1), as well as antibodies in sera of patients after mild and severe COVID-19 course. (A) Reciprocal
304 titers of SARS-CoV-2 neutralizing antibodies (nAb) were measured in focus reduction neutralization assay with
305 90 % inhibition (FRNT₉₀). (B) RBD IgGAM signals determined as sample/cut-off ratios (C) S1 quant IgG
306 antibodies were quantitatively measured in binding antibody units per milliliter (BAU/ml). (D-E) S1-IgA and
307 inactivated SARS-CoV-2 whole virus IgG signals (IWV) were determined as sample/calibrator ratios

308 The horizontal dotted lines represent positivity cut-offs. Statistical analysis was performed with ordinary 1-way
309 ANOVA, Holm-Sidak's multiple comparison test * = $p < 0.05$, ** = $p < 0.01$, *** = $p < 0.001$, **** = $p < 0.0001$, ns
310 = not significant

311 x-marked data points represent vaccinees with a previous SARS-CoV-2 infection

312

313 The correlation between BNT162b2-induced S1 IgG, RBD IgGAM antibody signals and nAb
314 titers using Spearman's rank coefficient is presented in S1 Fig. Herein, S1 IgG and RBD
315 IgGAM antibodies indicated the strongest correlation to SARS-CoV-2 nAbs ($r=0.93$) (Fig 3 A-
316 B), whereas IWV and S1-IgA correlation coefficients ranged between $r=0.722$ and 0.817 (S1
317 Fig C-D).

318 **Fig 3** Ratios between SARS-CoV-2 neutralizing antibody titers and (A, C, D) RBD IgGAM, S1 IgA, IWV in
319 sample/calibrator ratios and (B) S1 quant IgG in BAU/ml. Sera of vaccinees two weeks after second vaccination
320 (P1) were compared with sera of COVID-19 patients with mild and severe courses according to WHO score (2-3
321 mild and 4-5 severe). Statistical analysis was performed with an ordinary 1-way ANOVA, Holm-Sidak's multiple
322 comparison test * = $p < 0.05$, ** = $p < 0.01$, *** = $p < 0.001$, **** = $p < 0.0001$, ns = not significant.

323

324 The heterologous AZ/BNT vaccination cohort showed similar nAb titers after the first dose in
325 comparison to BNT162b2 vaccinees (S2 Fig). However, after the second vaccination
326 significantly higher nAb titers (4 fold increase) were detected compared to the homologous
327 mRNA vaccine group.

328

329 **Comparison of binding and neutralizing SARS-CoV-2 antibodies**

330 Ratios of binding to neutralizing antibodies were calculated to compare the proportion of
331 neutralizing antibodies induced by vaccination to convalescent individuals in each test (Fig 3).
332 Vaccinees presented a significantly lower proportion of neutralizing to S1 binding antibodies
333 in comparison to the COVID-19 group (10- fold and 5-fold lower for S1 IgG and S1 IgA
334 respectively). Similarly, this ratio was lower for RBD binding IgGAM antibodies compared to
335 patients after severe COVID-19 but was found comparable to the mild COVID-19 group. For
336 IWV-IgG the neutralizing proportion of binding antibodies was higher than in patients with
337 mild COVID-19 courses but below the median of severe courses.

338

339 **Long term kinetics of antibody titers**

340 The kinetics of antibody abundance varied greatly, with a mean reduction of nAb by 3.3 fold at
341 P2 and 9.7 fold at timepoint P3 compared to timepoint P1 two weeks after second vaccination.
342 (Fig 4 A) RBD IgGAM ratios decreased 1.8 fold after three month and 4.0 fold after eight
343 month (Fig 4 C). S1 antibody concentrations fall 5.7 fold at timepoint P2 and 36.6 fold at P3
344 (Fig 4 C). Smallest differences were observed in the IWV IgG antibody signals with a 1.1 fold
345 mean reduction after three months and a 2.2 fold mean reduction after eight month (Fig 4 D).

346 **Fig 4** BNT162b2-induced antibody levels 2 weeks, 3 and 8 month after second vaccination. (A) Reciprocal titers
347 of SARS-CoV-2 neutralizing antibodies were measured in focus reduction neutralization assay with inhibitor titer

348 90% (FRNT90). (B) RBD IgGAM signals were determined as sample/calibrator ratios (C) S1 IgG antibodies were
349 quantitatively measured in binding antibody units per milliliter (BAU/ml). (D-E) S1 IgA and IWV (SARS-CoV-2
350 inactivated whole-virion) titers were determined as sample/calibrator ratios. (F) Fold reduction of SARS-CoV-2
351 neutralizing antibody titers, RBD IgGAM, S1 IgG, S1 IgA and IWV IgG antibody signals in follow-up vaccine
352 sera calculated as ratio of value on timepoint P1 to timepoint P3.

353

354 **Neutralizing effect of BNT162b2-induced antibodies on B.1.617.2 and B.1.351 VOCs**

355 Neutralizing antibody titers were decreased towards VOCs in almost all tested individuals and
356 cohorts when compared with wildtype SARS-CoV-2 (Fig 5). A 5.1- and 11.5-fold mean titer
357 decrease was observed with the B.1.617.2 and B.1.351 variant, respectively. With 6.2-fold and
358 7.7-fold a similar nAb mean reduction was observed for both variants at P2. After eight month
359 nAb titers for B.1.617.2 showed a 6.2 fold and for B.1.351 a 4.1 fold decrease. Compared to
360 the homologous BNT/BNT vaccination group and Covid 19 convalescent group, the decrease
361 of nAbs against VOCs was much smaller (2.5- to 3.5-fold decrease) in the heterologous
362 AZ/BNT vaccination cohort (S3 Fig).

363 **Fig 5** BNT162b2- and infection induced reciprocal SARS-CoV-2 nAb titers on the wild-type strain wt-BavPat1
364 and the VOC strains B.1.617.2 and B.1.351 at timepoint P1 to timepoint P3. The dotted line indicates the limit-of-
365 detection at a titer of 1:5. FRNT90: focus reduction neutralization titer at 90% virus inhibition; results plotted as
366 reciprocal values. Mean neutralizing titer reductions of SARS-CoV-2 wt to VOC-nAb are depicted above the
367 continuous lines * = $p < 0.05$, ** = $p < 0.01$, *** = $p < 0.001$, **** = $p < 0.0001$, ns = not significant

368

369 **Impact of booster vaccination to nAb titer level on wildtype, B.1.617.2 and B.1.351 strains**

370 Two weeks after booster vaccination nAb titers are significantly higher compared to time point
371 P1 after second vaccination. The median increase reaches from 6.1 fold for wildtype variant to
372 26.2 fold in B.1.351 (Fig 6 A). The comparison between time point P3 and boost shows median
373 increase ranges between 76.3 fold and 138 fold (Fig 6 B).

374 **Fig 6** BNT162b2- induced reciprocal SARS-CoV-2 nAb titers on the wild-type strain wt-BavPat1 and the VOC
375 strains B.1.617.2 and B.1.351. (A) Nab titers were compared two weeks after second and third vaccination. (B)
376 Comparison of nAbs 8 month after second and two weeks after third vaccination. The dotted line indicates the
377 limit-of-detection at a titer of 1:5. FRNT90: focus reduction neutralization titer at 90% virus inhibition; results
378 plotted as reciprocal values. Mean neutralizing titer reductions of SARS-CoV-2 wt to VOC-nAb are depicted
379 above the continuous lines * = $p < 0.05$, ** = $p < 0.01$, *** = $p < 0.001$, **** = $p < 0.0001$, ns = not significant

380 **Validation of a dried blood spot based surrogate assay for SARS-CoV-2 nAbs**

381 FRNT-suggested nAb titers in serum samples were highly comparable ($r=0.664$) (S4 Fig) to
382 concentration of neutralizing surrogate antibodies in DBS, as further outlined in the
383 Supplementary material.

384

385 **Detection of SARS-CoV-2 targeting antibodies in saliva samples**

386 Saliva samples from vaccinees and COVID-19 patients with moderate or severe courses were
387 assessed for S1- and RBD-specific IgA antibodies using a sensitivity-trimmed bead-based flow-
388 cytometric assay. Based on interquartile range calculation, no increase of IgA production at V2
389 or P1 was observed in the group of BNT162b2-vaccinated individuals. Similar results were
390 obtained for the AZ/BNT group (data not shown). In contrast, most COVID-19 patients had
391 detectable salivary IgA towards SARS-CoV-2 antigens after 15-30 days after the onset of
392 symptoms (Fig 7).

393 **Fig 7.** Salivary IgA specific to SARS-CoV-2 RBD in individuals prior first (**V1**), three weeks after first (**V2**) and
394 to weeks after second vaccination (**P1**) in comparison with COVID-19 patients. The dotted line indicates the 95%
395 interquartile range for vaccinees.

396

397 **DISCUSSION**

398 **Impact of vaccination against SARS-CoV-2 on antibody formation**

399 Vaccination with mRNA- or vector-based vaccines represents a milestone in combating the
400 SARS-CoV-2 pandemic. To better understand their protective effects, we assessed the antibody
401 formation quantitatively and functionally after vaccination in comparison with natural SARS-
402 CoV-2 infections. Three weeks after the first vaccination with BNT162b2, in half of the subjects
403 nAbs could be detected, which is of note with regard to recent studies linking early levels of
404 nAbs with protection against SARS-CoV-2.[12] This suggests a presumably protective effect

405 already after the first vaccination with the BNT162b2 mRNA vaccine. Two weeks after the
406 second dose, all individuals developed high S1- and RBD-binding as well as SARS-CoV-2 nAb
407 titers. These results are in concordance with similar observations in studies on the mRNA-1273
408 vaccine.[13] Interestingly, an even stronger nAb production was observed in the group of
409 heterologous ChAdOx1-S/BNT162b2 vaccinated individuals. This indicates that a combination
410 of different SARS-CoV-2 vaccine classes leads to stronger humoral immune response which
411 may result in a better protective effect, as has also been shown by other studies. [14-17].

412

413 **Long-term kinetics of SARS-CoV-2 antibody response after BNT162b2 vaccination**

414 We have observed significant reduction of vaccine-induced antibody levels three months after
415 the second vaccination. Interestingly, S1 quant IgG and IgA antibodies decreased strongly,
416 whereas nAb levels and RBD-GAM dropped to a lesser extent.[18] Thus, the S1 quant IgG
417 ELISA does not seem to be an optimal diagnostic choice for determining longevity of humoral
418 immune responses after SARS-CoV-2 mRNA vaccination. Therefore, we propose the use of
419 RBD-IgGAM determination as a rapid and simple surrogate marker to estimate the levels of
420 nAbs after SARS-CoV-2 mRNA vaccination. One explanation for a better correlation between
421 RBD-IgGAM and nAbs could be a better RB-Domain presentation in the vaccine antigen.
422 Considering that a broader nAb production against the RBD region was observed in vaccinees
423 compared to COVID-19 patients.[19] Furthermore, as an alternative with potential for the easier
424 handling of study samples we introduced a new method to detect surrogate nAbs from dry blood
425 spot cards, and results from this assay highly correlated with the nAb data obtained in a classical
426 virus neutralization test. Of note, for any serological test addressing protective responses,
427 suitable cut-off levels reflecting the biological relevance would have to be determined within
428 future studies in larger patient cohorts.

429 As an observed decrease in SARS-CoV-2 antibody titers within a short diagnostic interval
430 might lead to the demand of booster vaccination doses, it is important to also investigate the
431 cellular and memory immune responses in order to provide a full picture of SARS-CoV-2
432 protection. Data from recovered COVID-19 patients implies the presence of memory B- and T-
433 cells in almost all individuals up to eight months after SARS-CoV-2 infection.[5, 20]

434

435 **Vaccination or SARS-CoV-2 infection induced nAbs against SARS-CoV-2 VOCs**

436 The BNT162b2 vaccine was designed using the spike gene sequence of the original Wuhan
437 SARS-CoV-2 wildtype virus. During the pandemic spread of SARS-CoV-2, mutations created
438 many viral variants and some of these mutations resulted in structural changes in the S protein,
439 thereby providing higher selection potential for increased transmission and pathogenicity of the
440 virus.[21, 22] In BNT/BNT vaccinees, our data revealed a 5.1-fold reduction in the
441 effectiveness of neutralizing antibodies against the B.1.617.2 VOC, thereby providing further
442 evidence for mRNA vaccination efficacy against this variant. For B.1.351, a significant 11.5-
443 fold reduction in neutralizing capacity was observed in vaccinees. These results agree with
444 recent studies.[23-25]

445 Data of individuals that were vaccinated with ChAdOx1-S and subsequently with BNT162b2
446 showed a lesser reduction of nAbs targeting VOCs. This leads to the conclusion that the
447 combination of both vaccines results in more robust immune response regarding VOC
448 infections. Of note, the group size for the heterologous vaccination is rather small compared
449 with the homologous mRNA vaccinated one. Therefore, the data need to be re-confirmed with
450 a larger cohort.

451 The booster immunization led to a significantly stronger production of SARS-CoV-2 specific
452 nAbs compared to the threshold after second vaccination. Of note, the median increase was

453 even more pronounced for VOC variants. Eight months after second vaccination nAb titers
454 were reduced by a 10-fold factor. In some individuals, for B.1.617.2 and B.1.351 variants
455 antibody titers were even below the limit of detection of the FRNT assay.

456 The decline in the neutralizing serological effect in recovered patients is however more
457 pronounced. Here, we observed a 21.5- to 34.7-fold decrease in nAb titers for patients with mild
458 and a 34-to 75.3-fold reduction for patients with severe COVID-19 courses. In other studies, a
459 3.5-fold reduction against B.1.351 was reported in convalescent patients compared to the
460 wildtype virus.[26] One third of the individuals with mild COVID-19 did not show any
461 detectable nAbs against B.1.1.7 and B.1.351 at all.

462

463 **BNT162b2 vaccination and mucosal immune response**

464 Generation of an intermittent protective mucosal immunity is generally accepted in COVID-19
465 patients undergoing natural infection and constitutes a relevant component in the suppression
466 of pandemic SARS-CoV-2 dissemination. However, using available COVID-19 mRNA and
467 vector-based vaccines, an immune response of mucosa associated lymphoid tissue (MALT) is
468 highly questionable. The protection of most systemic vaccinations against mucosal infection
469 solely relies on few circulating IgA and IgG antibodies which transudate from sera into the
470 mucosa.[27] These results suggest that SARS-CoV-2 mRNA vaccination is not able to trigger
471 a detectable protective mucosal immune response. However, other groups recently detected S1
472 IgG antibodies in saliva of vaccinated healthcare workers, which might however be attributable
473 to undiscovered natural SARS-CoV-2 infections that occurred previously.[28] Additional
474 development of mucosal vaccines could be crucial to improve the suppression of the pandemic
475 spread of future potential SARS-CoV-2 VOCs.

476

477 **Conclusions**

478 BNT162b2 mRNA vaccination provided sustainable formation of SARS-CoV-2 neutralizing
479 antibodies in our studied cohort. To preserve detectable nAb titers after 6 months, a booster
480 vaccination should be considered, especially for the protection against variants of concern. A
481 heterologous vaccine regime involving ChAdOx1-S vector-based prime and BNT162b2 mRNA
482 vaccine boost even exceeded these titers of neutralizing antibodies and might thus feature
483 beneficial synergy. None of the studied vaccines induced detectable mucosal immune response.

484

485 **Author contributions and conflict-of-interest disclosure**

486 O.N., J.W. and S.B. designed the study, performed assays, analyzed results and wrote the manuscript. A.R., J.F.
487 and S.U. performed assays, conducted analyses and wrote the manuscript. S.L., S.K., N.K., M.B. and C.L. recruited
488 probands/patients, critically discussed hypotheses and revised the manuscript. None of the authors declare
489 competing conflicts of interest.

490

491 **Funding and acknowledgements**

492 This publication was supported by the Saxon State Ministry for Science, Culture and Tourism (grant SaxoCOV)
493 and the European Virus Archive GLOBAL (EVA-GLOBAL) project that has received funding from the European
494 Union's Horizon 2020 research and innovation program under grant agreement No 871029. Furthermore, the
495 ImmunoDeficiencyCenter Leipzig received founding from the Jeffrey Modell Foundation for Primary
496 immunodeficiency diseases.

497 The authors are indebted to the voluntary help of probands and patients to participate in this study. Furthermore,
498 we would like to particularly emphasize the efforts made by Ulrike Schmidt and Cathrin Crimmann, and all
499 participating doctors and nurses during the vaccination campaign. Moreover, we like to thank Ulrike Ehlert and
500 Steffen Jakob for their excellent technical assistance. We also thank Corinna Pietsch (Leipzig University Hospital)
501 and Klaus Überla (Erlangen-Nürnberg University) for supplying VOCs.

502

503 Literature

- 504 1. Thomas SJ, Moreira ED, Jr., Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and
505 Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. *N Engl J Med*. 2021;385(19):1761-
506 73.
- 507 2. Huang AT, Garcia-Carreras B, Hitchings MDT, Yang B, Katzelnick LC, Rattigan SM, et al. A
508 systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection,
509 and association with severity. *Nat Commun*. 2020;11(1):4704.
- 510 3. Rockstroh A, Wolf J, Fertey J, Kalbitz S, Schroth S, Lubbert C, et al. Correlation of humoral
511 immune responses to different SARS-CoV-2 antigens with virus neutralizing antibodies and
512 symptomatic severity in a German COVID-19 cohort. *Emerg Microbes Infect*. 2021;10(1):774-81.
- 513 4. Turner JS, Kim W, Kalaidina E, Goss CW, Rauseo AM, Schmitz AJ, et al. SARS-CoV-2 infection
514 induces long-lived bone marrow plasma cells in humans. *Res Sq*. 2020. Epub 2021/01/06. doi:
515 10.21203/rs.3.rs-132821/v1.
- 516 5. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-
517 CoV-2 assessed for up to 8 months after infection. *Science*. 2021;371(6529).
- 518 6. Makoni M. South Africa responds to new SARS-CoV-2 variant. *Lancet*. 2021;397(10271):267.
- 519 7. Singh J, Rahman SA, Ehtesham NZ, Hira S, Hasnain SE. SARS-CoV-2 variants of concern are
520 emerging in India. *Nat Med*. 2021;27(7):1131-3.
- 521 8. Alkharaan H, Bayati S, Hellstrom C, Aleman S, Olsson A, Lindahl K, et al. Persisting Salivary IgG
522 Against SARS-CoV-2 at 9 Months After Mild COVID-19: A Complementary Approach to Population
523 Surveys. *J Infect Dis*. 2021;224(3):407-14.
- 524 9. BNT162b2 Fact sheet 2021 [18.08.2021]. Available from:
525 [https://www.ema.europa.eu/en/documents/product-information/comirnaty-epar-product-](https://www.ema.europa.eu/en/documents/product-information/comirnaty-epar-product-information_en.pdf)
526 [information_en.pdf](https://www.ema.europa.eu/en/documents/product-information/comirnaty-epar-product-information_en.pdf).
- 527 10. ChAdOx1-S Fact sheet: EMA; 2021 [18.08.2021]. Available from:
528 [https://www.ema.europa.eu/en/documents/product-information/vaxzevria-previously-covid-19-](https://www.ema.europa.eu/en/documents/product-information/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_en.pdf)
529 [vaccine-astrazeneca-epar-product-information_en.pdf](https://www.ema.europa.eu/en/documents/product-information/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_en.pdf).
- 530 11. Peter AS RE, Schulz SR, et al. A pair of non-competing neutralizing human monoclonal
531 antibodies protecting from disease in a SARS-CoV-2 infection model. *bioRxiv*. 2021. doi:
532 2021.04.16.440101.
- 533 12. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody
534 levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nat Med*.
535 2021. Epub 2021/05/19. doi: 10.1038/s41591-021-01377-8.
- 536 13. Jackson LA, Anderson EJ, Roupheal NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA
537 Vaccine against SARS-CoV-2 - Preliminary Report. *N Engl J Med*. 2020;383(20):1920-31.
- 538 14. Liu X, Shaw RH, Stuart ASV, Greenland M, Aley PK, Andrews NJ, et al. Safety and
539 immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral
540 vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.
541 *Lancet*. 2021. Epub 2021/08/10. doi: 10.1016/S0140-6736(21)01694-9.
- 542 15. Groß R ZM, Seidel A, Conzelmann C, Gilg A, Krnavek D, Erdemci-Evin S, Mayer B, Hoffmann M,
543 Pöhlmann S, Beil A, Kroschel J, Jahrsdörfer B. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-
544 boost vaccination elicits potent neutralizing antibody responses and T cell reactivity. *medRxiv*. 2021.
545 doi: <https://doi.org/10.1101/2021.05.30.21257971>.
- 546 16. Tenbusch M, Schumacher S, Vogel E, Priller A, Held J, Steininger P, et al. Heterologous prime-
547 boost vaccination with ChAdOx1 nCoV-19 and BNT162b2. *Lancet Infect Dis*. 2021. Epub 2021/08/02.
548 doi: 10.1016/S1473-3099(21)00420-5.
- 549 17. Nordstrom P, Ballin M, Nordstrom A. Effectiveness of heterologous ChAdOx1 nCoV-19 and
550 mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide
551 cohort study. *Lancet Reg Health Eur*. 2021;11:100249.

- 552 18. Van Elslande J, Gruwier L, Godderis L, Vermeersch P. Estimated half-life of SARS-CoV-2 anti-
553 spike antibodies more than double the half-life of anti-nucleocapsid antibodies in healthcare workers.
554 Clin Infect Dis. 2021. Epub 2021/03/12. doi: 10.1093/cid/ciab219.
- 555 19. Greaney AJ, Loes AN, Gentles LE, Crawford KHD, Starr TN, Malone KD, et al. The SARS-CoV-2
556 mRNA-1273 vaccine elicits more RBD-focused neutralization, but with broader antibody binding within
557 the RBD. bioRxiv. 2021. Epub 2021/04/22. doi: 10.1101/2021.04.14.439844.
- 558 20. Sherina N, Piralla A, Du L, Wan H, Kumagai-Braesch M, Andrell J, et al. Persistence of SARS-
559 CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6-8 months after the infection.
560 Med (N Y). 2021;2(3):281-95 e4.
- 561 21. Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, et al. Detection of a
562 SARS-CoV-2 variant of concern in South Africa. Nature. 2021;592(7854):438-43.
- 563 22. Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, et al. Tracking Changes
564 in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. Cell.
565 2020;182(4):812-27 e19.
- 566 23. Zhou D, Dejnirattisai W, Supasa P, Liu C, Mentzer AJ, Ginn HM, et al. Evidence of escape of
567 SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell. 2021;184(9):2348-61 e6.
- 568 24. Hoffmann M, Arora P, Gross R, Seidel A, Hornich BF, Hahn AS, et al. SARS-CoV-2 variants
569 B.1.351 and P.1 escape from neutralizing antibodies. Cell. 2021;184(9):2384-93 e12.
- 570 25. Jalkanen P KP, Häkkinen H, et al. COVID-19 mRNA vaccine induced antibody responses and
571 neutralizing antibodies against three SARS-CoV-2 variants. Research Square. 2021. doi:
572 10.21203/rs.3.rs-343388/v1
- 573 26. Edara VV, Norwood C, Floyd K, Lai L, Davis-Gardner ME, Hudson WH, et al. Infection- and
574 vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant. Cell Host
575 Microbe. 2021;29(4):516-21 e3.
- 576 27. Mudgal R, Nehul S, Tomar S. Prospects for mucosal vaccine: shutting the door on SARS-CoV-2.
577 Hum Vaccin Immunother. 2020;16(12):2921-31.
- 578 28. Azzi L, Dalla Gasperina D, Veronesi G, Shallak M, Ietto G, Iovino D, et al. Mucosal immune
579 response in BNT162b2 COVID-19 vaccine recipients. EBioMedicine. 2021;75:103788.

580




Figure 1




Figure 2




Figure 3




Figure 4

medRxiv preprint doi: <https://doi.org/10.1101/2022.01.29.22270066>; this version posted January 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).




Figure 5



A**B**

Figure 6




Figure 7